Skip to main content

Merck KGaA, Millipore Get US Clearance for Acquisition

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Merck KGaA's agreement to acquire Millipore has cleared US anti-trust review, Millipore said in a filing today with the US Securities and Exchange Commission.

The firms agreed to the deal at the end of February. Under terms of the deal, Darmstadt, Germany's Merck will pay $107 per share for all of Millipore's stock for a total transaction value of roughly $7.2 billion. The deal values Millipore at 4.4 times its 2009 sales of $1.65 billion.

Millipore said in its SEC filing that the waiting period for a review by the US Department of Justice and the Federal Trade Commission had expired without a request for any additional information.

In early Wednesday afternoon trade on the New York Stock Exchange, shares of Millipore were up less than 1 percent at $106.22 per share.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.